GlassScriptPhysician profile
Laurie Childs
NPI 1235355819
$2,666.36
in general payments reported to CMS, 2019-2025
25 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2022: $875 · 2023: $421 · 2024: $364 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,098.77 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $264.24 | 2021-2023 | Nucala |
| Pharming Healthcare, INC. | $148.83 | 2022-2023 | Ruconest |
| Kaleo, INC. | $129.50 | 2021-2024 | Auvi-Q |
| Csl Behring | $115.99 | 2022-2025 | Hizentra |
| Grifols USA, LLC | $113.11 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Teva Pharmaceuticals USA, INC. | $86.82 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $74.63 | 2021-2023 | Orladeyo |
| Genzyme Corporation | $67.26 | 2021-2025 | |
| Bio Products Laboratory USA, INC. | $63.50 | 2021-2022 | |
| Optinose US, INC. | $58.28 | 2022-2024 | |
| Pfizer INC. | $52.26 | 2021-2024 | |
| Adma Biomanufacturing LLC | $51.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.14 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.26 | 2025 | Eohilia, Takhzyro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.85 | 2023 | Spiriva Respimat, Spiriva |
| Octapharma USA, INC. | $33.37 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.92 | 2021-2024 | Dupixent |
| Abbvie INC. | $23.94 | 2022 | |
| Kedrion Biopharma, INC. | $22.79 | 2024 | Kedrab, Gammaked, Koate |
| Ars Pharmaceuticals Operations, INC. | $22.42 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $20.55 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $20.28 | 2021 | |
| Tersera Therapeutics LLC | $17.79 | 2025 | Quzyttir |
| Amgen INC. | $17.33 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.